Background Microvascular and macrovascular thrombotic events are among the hallmarks
of coronavirus disease 2019 (COVID-19). Furthermore, the exuberant immune response is …

Importance Thrombotic events are commonly reported in critically ill patients with COVID-19.
Limited data exist to guide the intensity of antithrombotic prophylaxis. Objective To evaluate …

Abstract Background: COVID-19–related critical illness is associated with an increased risk
of venous thromboembolism (VTE). Objective: These evidence-based guidelines of the …

Clinical, laboratory, and autopsy findings support an association between coronavirus
disease-2019 (COVID-19) and thromboembolic disease. Acute COVID-19 infection is …

Background: The efficacy and safety of prophylactic full-dose anticoagulation and
antiplatelet therapy in critically ill COVID-19 patients remain uncertain. Methods: COVID …

Background Thrombotic complications are considered among the main extrapulmonary
manifestations of coronavirus disease 2019 (COVID-19). The optimal type and duration of …

Abstract Background Coronavirus disease 2019 (COVID‐19) is associated with
coagulopathy but the optimal prophylactic anticoagulation therapy remains uncertain and …

Despite the emergence of high quality randomized trial data with the use of antithrombotic
agents to reduce the risk of thromboembolism, end‐organ failure, and possibly mortality in …

Background Data on thrombosis and current real-world management strategies for
anticoagulation therapy are scarce but important for understanding current issues and …

Background Anticoagulation in hospitalized COVID-19 patients has been associated with
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …